Market
Which major companies will partner with AstraZeneca and Daiichi Sankyo for their treatment by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Novartis • 25%
None of the above • 25%
Press releases and partnership announcements from AstraZeneca, Daiichi Sankyo, and other pharmaceutical companies
Story
AstraZeneca and Daiichi Sankyo Win First U.S. Approval for Novel Breast Cancer Treatment; Stock Rises Most in Five Months
Jan 19, 2025, 05:37 PM
AstraZeneca and Daiichi Sankyo have received U.S. approval for a novel breast cancer treatment, marking a significant milestone in their efforts to establish the drug as a widely used option in oncology. This approval represents the first authorization for this closely monitored treatment, which has prompted a notable increase in Daiichi Sankyo's stock, rising the most in five months. The approval was confirmed by multiple sources, including the FDA and various news outlets.
View original story
Similar markets
No • 50%
Yes • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Eli Lilly • 25%
Other • 25%
AstraZeneca • 25%
Roche • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Pfizer • 25%